Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cellnovo Group

Request full access

Diabetes management system

Paris, FranceFounded 2002Health

About Cellnovo Group

Cellnovo Group SA was a medical technology company focused on the diabetes management market. Founded in 2002 and headquartered in Paris, France, the firm set out to develop a comprehensive, mobile-first system for diabetic patient care. The company's flagship product was the Cellnovo System, an all-in-one diabetes management platform. This system featured a discreet, wearable micropump for insulin delivery that communicated via Bluetooth with a dedicated, locked-down Android smartphone. This handset also contained an integrated blood glucose meter, creating a singular device for tracking and treatment.

A key feature of the Cellnovo platform was its connectivity. The system was designed to automatically transmit patient data in real-time, allowing for continuous monitoring by family members and healthcare professionals. This aimed to provide peace of mind and facilitate better management of the patient's condition. The business model centered on the sale of the hardware system—the pump and handset—and the recurring revenue from proprietary insulin cartridges. The company targeted the global market for insulin pumps, which was estimated to be worth over $2 billion. After obtaining a CE Mark, the product was commercialized in several countries, including France, the UK, the Netherlands, and Australia.

Despite showing strong sales growth in its final year of operation, with revenues more than doubling in 2018 after scaling up production of its insulin cartridges , Cellnovo faced significant operational hurdles. In March 2019, the company announced it was ceasing manufacturing and commercial operations. Sophie Baratte, who was the CEO at the time, cited challenges in scaling up production in a competitive and cost-pressured market as the primary reason for this decision. The company's UK subsidiary entered administration, and the parent company in France subsequently filed for judicial liquidation in April 2019 after failing to find a buyer for the entire group. The majority of the group's assets, including its intellectual property, were held by its UK subsidiary, Cellnovo Limited.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2015

Cellnovo Group in the Paris ecosystem

Live from Dealroom

The Cellnovo Group office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Omnes Capital
  • Auriga Partners
  • Andera Partners
  • Advent Venture Partners
  • NBGI Ventures
  • Forbion Capital Partners
  • Nesta Impact Investments
  • HealthCare Ventures

Series B and later2 investors entered at this stage

  • Kreos Capital
  • ALIAD (Air Liquide)
Team profiled 28 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇫🇷 France10%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cellnovo Group on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cellnovo Group on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.